When failure should be the option by Petsko, Gregory A
Give me your tired, your poor, your Phase II failures… 
Well, OK, to be honest, I’m not sure I want your tired or 
your poor, and besides, The Statue of Liberty has that 
pretty well covered. But I am sure that I want your Phase 
II failures. I REALLY want your Phase II failures.
Before  I  explain  what  I  mean,  I  should  review  the 
progress in making drugs to treat serious human illnesses 
in  the  first  decade  of  the  21st  century  -  or,  more 
accurately, the lack of progress. While it’s been true for a 
long  time  that  about  the  hardest  thing  human  beings 
have ever tried to do is to make a drug, it seems as though 
lately  it’s  got  even  harder.  The  number  of  new  thera-
peutics approved for use on humans, per year, has been 
essentially flat for more than two decades. During this 
time,  new  technologies  such  as  structure-based  drug 
discovery have been created, pharmaceutical companies 
have  merged  to  form  giant  entities,  and  hundreds  of 
biotechnology  companies  have  been  launched  to  rival 
them, the research expenditure of the National Institutes 
of Health (NIH) has more than doubled, and the R&D 
budget of the drugs industry has shot up. Yet despite all 
that, we are not developing new drugs any faster than we 
did before. Why not?
One reason is that the diseases we are now trying to 
treat, such as cancer and Alzheimer’s disease, are harder 
than many of the infectious diseases that dominated our 
efforts 50 years ago. But another reason lies in the nature 
of the drug development process itself.
For every drug that is used clinically to treat a disease, 
more than 6,000 completely new chemical compounds 
are synthesized. On average, about 20 drug candidates 
are tested in people for every one that gets to market. 
(The  failure  rate  for  biopharmaceuticals,  which  are 
macro  molecules rather than small organic compounds, is 
a lot better, but still very high: about one in five of those 
candidates tested in humans make it to the clinic.) For 
chemical drugs the process takes, on average, about 12 
years  from  target  identification  to  drug  approval  and 
costs  close  to  US$1  billion  (the  timeline  is  shorter  for 
biopharmaceuticals and the overall cost is only about a 
third  of  this,  in  part  because  there  are  fewer  failures). 
More than half the cost comes from the clinical trials that 
must  be  undertaken  once  a  drug  candidate  has  been 
approved for human testing. This approval comes at the 
end of an extensive period of preclinical testing, which 
involves in vitro (test tube) and in vivo (animal or cell 
culture)  experiments  using  wide-ranging  doses  of  the 
study  drug  to  obtain  preliminary  efficacy,  toxicity  and 
pharmacokinetic data (data on absorption, distribution, 
metabolism and excretion, popularly known as ADME) 
in animal models of the disease in question. Such tests 
allow  pharmaceutical  companies  to  decide  whether  a 
drug  candidate  warrants  further  development  as  an 
investi  gational new drug.
In  the  United  States,  which  is  both  the  largest  drug 
maker and the largest single drug market in the world, 
the next step is the clinical trial process, which has three 
main phases. Phase I trials are the first stage of testing in 
human subjects. Normally, a small (20 to 100) group of 
healthy volunteers is selected. They are given the drug to 
assess  its  safety,  tolerability,  pharmacokinetics  and 
pharmaco  dynamics  in  people.  These  trials  are  often 
conducted in an in-patient clinic, where the subject can 
be observed by full-time staff. Phase I trials also include 
dose-ranging, also called dose escalation, studies so that 
the  appropriate  dose  for  therapeutic  use  can  be  esti-
mated. The tested range of doses will usually be a fraction 
of the dose that caused harm in the preclinical animal 
testing.  Although  Phase  I  trials  typically  use  healthy 
human volunteers, there are circumstances in which real 
patients  are  used,  such  as  patients  who  have  terminal 
cancer or are infected with HIV and lack other treatment 
options.
Once the initial safety of the drug candidate has been 
confirmed in Phase I trials, Phase II trials are performed 
on larger groups (20 to 300), this time of patients. Phase 
II trials are designed to assess how well the drug works 
on the disease in question, as well as to continue Phase I 
safety  assessments  in  a  larger  group  of  volunteers  and 
patients.  Phase  II  studies  are  sometimes  divided  into 
Phase IIA and Phase IIB, where Phase IIA is specifically 
designed to assess dosing requirements (how much drug 
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designed to study efficacy (how well the drug works at 
the prescribed dose(s)).
Phase  III  studies  are  randomized,  controlled,  multi-
center trials on large patient groups (usually 300 to 3,000 
or more depending upon the disease/medical condition 
studied) and are aimed at being the definitive assessment 
of how effective the drug is in comparison with current 
‘gold standard’ treatment for the disease. Because of their 
size and comparatively long duration, Phase III trials are 
the most expensive, time-consuming and difficult trials 
to  design  and  run,  especially  in  therapies  for  chronic 
medical conditions. While not required in all cases, it is 
typically expected that there be at least two successful 
Phase  III  trials  in  order  to  obtain  approval  from  the 
appropriate  regulatory  agencies  such  as  the  Food  and 
Drug Administration (FDA) (in the United States), or the 
European Medicines Agency (EMEA) (in the European 
Union), for example. Once a drug has proved satisfactory 
after Phase III trials, the trial results are usually combined 
into a large document containing a comprehensive des-
crip  tion  of  the  methods  and  results  of  all  human  and 
animal studies, the manufacturing procedures, formula-
tion details, and shelf life. This collection of information 
makes up the ‘regulatory submission’ that is provided for 
review to the regulatory agencies. They will review the 
submission and make the final decision on whether to 
grant  the  pharmaceutical  or  biotechnology  company 
approval  to  market  the  drug.  However,  many  drugs 
under  going  Phase  III  clinical  trials  can  be  marketed 
under  FDA  norms  with  proper  recommendations  and 
guidelines (after all, they have been shown to be both safe 
and effective in the Phase I and Phase II studies), but in 
case of any adverse effects being reported anywhere, the 
drugs  will  be  recalled.  While  most  pharmaceutical 
companies refrain from this practice, it is possible to see 
drugs  that  are  still  undergoing  Phase  III  clinical  trials 
being used in the clinic.
So, given that the failure rate for small-molecule thera-
peutics  is  about  19  out  of  20  once  clinical  trials 
commence (and 4 out of 5 for biologicals), where do you 
think  the  major  roadblock  is  to  approval?  If  you  said 
Phase I, because that is where toxicity (and side-effects) 
are  first  assessed,  you  said  what  I  once  thought,  and 
you’re wrong. It’s not in Phase III either; in fact, although 
failures in Phase III do occur (and often engender a lot of 
publicity),  most  drugs  that  enter  Phase  III  trials  are 
eventually approved. The bottleneck is in Phase II.
That’s  right:  after  years  of  research  and  hundreds  of 
millions of dollars, the majority of drugs that never get to 
market  fail  because  they  do  not  show  efficacy  in  the 
disease they were intended for. That’s a staggering fact, 
and it has a number of important implications. One of 
the implications is that our animal models for toxicity are 
pretty good (after all, the Phase II failures passed Phase I, 
which  looked  for  toxicity),  but  our  animal  and  cell-
culture  models  for  disease  are  very  poor  for  many 
diseases. In other words, we lack good models that would 
allow  us  to  validate  targets  and  fail  compounds  much 
earlier in the drug-development pipeline, when the cost 
would be much lower. If I were the pharmaceutical and 
biotech companies, I would be funding a lot of research 
in academic labs on the development of better disease 
models (induced pluripotent stem cells (iPS cells) may be 
a big advance here, but it’s too early to tell), and I would 
be working more closely with academic labs for longer 
periods  of  time  to  validate  targets  and  find  additional 
targets deeper into the development process.
But that isn’t my main point. My main point is that the 
Phase  II  failures  represent  an  enormous,  untapped 
resource  for  the  biomedical  sciences  -  a  resource  that 
could go a long way towards solving the problem of low 
productivity, in terms of cures, that plagues both industry 
and academic medicine.
You see, the Phase II failures have all passed Phase I, so 
they have been shown to be safe in humans. They failed 
for efficacy. They failed because they did not effectively 
treat the disease they were intended to treat, even though 
they  showed  biological  activity  in  assays  and  model 
systems.  There  are  hundreds  of  them  -  perhaps  more 
than a thousand. I don’t know the number because drug 
companies bury those failures. They don’t want to release 
a  lot  of  information  about  the  molecules  in  question 
because, among other things, they fear that will give their 
competitors too much of an insight into what they are 
working on. But here’s the question I would like you - and 
them - to ponder. What if those drugs were not tried on 
the right disease?
We now know that many quite different diseases share 
common pathways and processes in the cell. Cancer is a 
disease of abnormal cell survival; in Alzheimer’s disease 
the  survival  pathways  have  failed.  Alzheimer’s  patients 
have significantly lower risk of many cancers. What if the 
cure  for  Alzheimer’s  disease  is  sitting  on  some  drug 
company’s shelf, as a potential cancer drug that failed in 
Phase II? (A biotech company called Link Medicines is 
currently testing one such failure to find out.) Gaucher 
disease and Parkinson’s disease both involve lysosomal 
damage and display aggregates of a protein called alpha-
synuclein;  Gaucher  carriers  are  at  elevated  risk  for 
Parkinson’s.  What  if  a  drug  intended  to  cure  Gaucher 
disease, one that failed in Phase II, is actually a treatment 
for  Parkinson’s?  (Another  biotech  company,  Amicus 
Therapeutics, is beginning to investigate that possibility.) 
Recent studies show that people diagnosed with psoriasis 
are at greater risk of developing heart disease; in fact, in 
patients  with  severe  psoriasis  who  are  younger  than 
50  years  old,  the  risk  is  comparable  to  that  seen  in 
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ever been tested in heart disease clinical trials?
I could list literally a dozen more examples, but you get 
the  idea:  because  we  balkanize  biomedical  research, 
biomedical-research funding, and pharmaceutical industry 
drug development according to phenotypically classified 
diseases, the possibility that a drug that has failed the 
efficacy  test  in  one  disease  might  be  efficacious  in  a 
completely different one has not permeated the culture. 
Yet  we  should  not  be  surprised  if  such  cross-disease 
activity occurs, because these Phase II failures got as far 
as human clinical trials for a reason: they hit a target (or 
targets) in cell culture and animal models, and produced 
an effect. That they failed to do so in the human disease is 
an indictment of our disease models, not the biochemical 
and cellular data that showed they did something. What 
we need to do is test them on other diseases - a battery of 
other diseases - perhaps first in cell culture (iPS cells?) 
and  animal  models  and,  if  they  show  an  effect,  then 
directly in Phase II clinical trials for the new disease. (It 
may even be that we can proceed immediately to Phase II 
studies without the animal model testing (after all, our 
animal models aren’t very good) if we have mechanistic 
or other data to suggest that efficacy is possible in the 
unrelated disease.) The problem is that such tests usually 
cannot  be  done  by  the  original  developer,  because  no 
drug  company  has  programs  in  all  the  major  human 
diseases.  And  they  certainly  aren’t  going  to  let  their 
competitors test them. So who will do the tests?
Academic labs are the perfect answer. In most cases, 
they  discovered  the  disease  targets  and  developed  the 
disease models in the first place. Many of these labs are 
already trying to find compounds that show efficacy in 
those  models,  in  the  hope  that  a  pharmaceutical  or 
biotech  company  will  become  interested  in  developing 
them further. But they lack libraries of compounds to test 
that  are  known  to  be  safe  in  humans  and  that  are 
guaranteed to interact with something, anything, in the 
cell. The Phase II failures are a perfect library to test.
If  the  tests  are  successful,  who  would  take  the  next 
steps of funding the new Phase II clinical trials? It makes 
sense for such funding to come from the government, 
and there is a new program that might be an interesting 
way to do it. In the new health-care reform bill recently 
signed into law by US President Barack Obama, there is 
an  amendment  that  authorizes  the  NIH  to  establish  a 
$500 million a year program called the Cures Accelera-
tion  Network,  whose  mission  is  to  aid  in  establishing 
partnerships  between  academic  labs  and  industry  that 
would  accelerate  the  finding  of  cures  for  untreatable 
human  illnesses.  I  have  discussed  this  amendment  in 
more  detail  in  an  article  in  Genome  Biology  [1].  At 
present, there is no agreement on just how to fulfill that 
charge. I think finding new indications for some of the 
Phase II failures would be a great way to do that. Since 
they  already  have  passed  Phase  I,  they  are  very  much 
closer to approval than any set of random compounds 
from  other  libraries,  or  even  compounds  that  are 
currently in preclinical testing; all that is needed is to find 
the right disease for them, if one exists. $500 million per 
year would fund a number of Phase II clinical trials, as 
well as a grant program to identify academic labs to test 
the compounds in disease models for those cases where a 
second disease indication is not obvious from the biology. 
If efficacy is established against a new disease in humans, 
then  the  government  could  give  the  company  that 
originally  developed  the  compound  the  right  of  first 
refusal on an option to fund Phase III trials and then to 
market the drug. If that company was not interested, the 
government could hold a competition to select another 
company that would take the compound forward. In any 
case, the academic lab that established the new disease 
indication  would  get  some  royalties  from  the  sales,  as 
would the original developer.
Why should pharmaceutical companies be interested, 
given how jealously they guard their secrets? After all, the 
probability that one of their compounds will show any 
efficacy in a new disease is still quite low. However, there 
are some incentives, including especially good publicity, 
that might be persuasive - after all, the pharmaceutical 
industry  has  taken  a  big  beating  lately  in  the  court  of 
public  opinion.  It  also  might  be  possible  to  find  a 
legislative fix for some of their problems that could be 
traded  for  their  participation  in  a  Phase  II  failures 
program. And steps could certainly be taken to protect 
the confidentiality of some of the information about the 
compounds in question, at least for a time. We can find 
the right incentives if we try.
So  I  want  the  Phase  II  failures.  I  REALLY  want  the 
Phase II failures. I want them for my own research and 
for your research. I want them because they could make a 
difference for a host of unmet medical needs. And here’s 
my last question, aimed at patient advocacy groups and 
scientific  societies  and  medical  school  deans  and 
biotechnology  associations  and  government  officials 
everywhere: who wants to help me get them?
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